Ocrelizumab Linked to Improved Visual Outcomes in Relapsing MS Ocrelizumab Linked to Improved Visual Outcomes in Relapsing MS

In pooled analysis from the phase 3 OPERA trials, low-contrast letter acuity showed improved visual outcomes in MS after treatment with ocrelizumab over interferon beta-1a.Medscape Medical News

Source: Medscape Medical News Headlines - October 27, 2017 Category: Consumer Health News Tags: Neurology & Neurosurgery News Source Type: news